mRNA-LNP Formulation
Croyez provides advanced mRNA-LNP formulation services designed for high-efficiency nucleic acid delivery. Our platform achieves excellent encapsulation performance and offers customizable lipid compositions to meet diverse research and development needs.
We support a full spectrum of nucleic acid modalities—including mRNA, saRNA, and sgRNA—with optimized ionizable lipid systems tailored for superior transfection and stability.
For precision applications, targeted LNP formulations are also available to deliver payloads specifically to desired cells or tissue types, accelerating your path from formulation to preclinical validation.
We support a full spectrum of nucleic acid modalities—including mRNA, saRNA, and sgRNA—with optimized ionizable lipid systems tailored for superior transfection and stability.
For precision applications, targeted LNP formulations are also available to deliver payloads specifically to desired cells or tissue types, accelerating your path from formulation to preclinical validation.
Characteristics
- Ionizable lipid compositions: SM102, ALC0315, MC3
- Liquid format; customizable concentration (<0.2 mg/mL default)
- RNA size range: 500 nt – 12 k
- Scalable production: 0.1 mg to gram-scale RNA payloads
- Encapsulation Efficiency: >85%
- Size Distribution: POI ±20 nm
- Polydispersity Index: <0.2
- Zeta potential: ± 15 mV pH: 7.4 ± 0.5
1. mRNA Applications
Our LNP platform is optimized for diverse mRNA-based therapeutics, including:
- Vaccines: Development of prophylactic or therapeutic mRNA vaccines for infectious diseases (e.g., COVID-19, Influenza, RSV).
- Gene Replacement Therapy: Restoring or compensating for defective genes in rare genetic disorders.
- Protein Replacement Therapy: Expressing functional proteins to treat enzyme deficiencies or structural defects.
- Cancer Immunotherapy: Delivering mRNA encoding tumor neoantigens or immune-stimulatory molecules.
- Ex vivo Cell Engineering: Safe and transient transfection for CAR-T or immune cell modification without genomic integration.
2. saRNA / sgRNA Applications
- saRNA: For high-expression and low-dose vaccine or therapeutic applications.
- sgRNA (CRISPR Delivery): Compatible with Cas proteins for efficient genome editing.
Figure 1.
saRNA GFP / LNP transfection in BHK21 cells
BHK21 cells were incubated with 100 ng samRNA GFP/LNP for 18 hours. After changing to fresh growth medium, the cells were monitored for GFP expression and subcultured until 34 days
Figure 2.
saRNA GFP / LNP transfection in 293T cells
293T cells were incubated with 100 ng samRNA GFP/LNP for 18 hours. After changing to fresh growth medium, the cells were monitored for GFP expression and subcultured until 34 days
